Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. reports news on its radiopharmaceutical business, including diagnostic imaging agents, radiotherapeutic assets, regulatory decisions and financial results. The company organizes revenue around Radiopharmaceutical Oncology, Precision Diagnostics and Strategic Partnerships and Other Revenue, with products used by hospitals, independent imaging centers, government facilities and distribution partners in the United States and abroad.
Recurring updates include quarterly earnings, business guidance, FDA activity for products such as PYLARIFY TruVu, PYLARIFY, Lutetium Lu 177 Dotatate (PNT2003) and LNTH-2501, share repurchases, investor presentations and strategic updates involving radiodiagnostics and radiotherapeutic programs.
Lantheus (NASDAQ: LNTH) reported Q4 2025 worldwide revenue of $406.8 million and full year 2025 revenue of $1.54 billion. GAAP diluted EPS was $0.82 in Q4 and $3.41 for FY2025; adjusted diluted EPS were $1.67 and $6.08, respectively.
The company completed acquisitions, repurchased shares, divested its legacy SPECT business, and issued FY2026 guidance: $1.4–1.45 billion revenue and $5.00–5.25 adjusted EPS.
Lantheus (NASDAQ: LNTH) announced that Mary Anne Heino, Executive Chairperson and CEO, will present at two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:10 a.m. ET and Leerink Global Healthcare Conference on March 10, 2026 at 8:00 a.m. ET.
Live webcasts will be accessible via the Investors section of the company's website, with replays available for at least 30 days following each presentation.
Lantheus (NASDAQ: LNTH) will host a conference call and webcast at 8:00 a.m. ET on February 26, 2026 to discuss fourth quarter and full year 2025 financial and operating results. Participants should register online and are encouraged to register 15 minutes early to avoid delays.
A replay will be available approximately two hours after the webcast and archived on the events page for at least 30 days. Access registration at the company events calendar.
Lantheus (NASDAQ: LNTH) announced on January 2, 2026 that it has completed the sale of its SPECT business to SHINE Technologies. The divestiture transfers the SPECT diagnostic agents TechneLite, NEUROLITE, Xenon Xe-133, and Cardiolite, the portion of the North Billerica, Massachusetts campus that manufactures SPECT products, and SPECT-related Canadian operations to SHINE.
With the SPECT business closed, Lantheus will concentrate on its commercial PET radiodiagnostics and microbubbles and continue advancing its radiopharmaceutical pipeline. Financial, legal, and tax advisors to Lantheus on the transaction were disclosed.
Lantheus (NASDAQ: LNTH) will present new florbetaben F 18 data at Clinical Trials on Alzheimer’s Disease (CTAD) 2025, held December 1–4 in San Diego, CA. The company’s poster, titled "Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab", is scheduled for Wednesday, December 3, 2025, during Session 06: Clinical Trials: Imaging (Poster P184).
The poster will be presented by Marianne Chapleau, Life Molecular Imaging. The session runs from 7:15 AM to 5:30 PM PT on that day.
Lantheus (NASDAQ: LNTH) reported Q3 2025 revenue $384.0M, GAAP EPS $0.41 and adjusted EPS $1.27, with free cash flow $94.7M. The company closed the acquisition of Life Molecular Imaging in July and repurchased $100M of common stock in Q3. Management announced the planned retirement of CEO effective Dec 31, 2025 and the Board is conducting a CEO search. FDA PDUFA target action dates were set for a new piflufolastat F 18 formulation (Mar 6, 2026), LNTH-2501 Ga 68 kit (Mar 29, 2026) and MK-6240 (Aug 13, 2026). Updated FY2025 guidance: $1.49B–$1.51B revenue and $5.50–$5.65 adjusted EPS.
Lantheus (NASDAQ: LNTH) announced a planned leadership transition: CEO Brian Markison will retire effective Dec 31, 2025 and will serve as strategic advisor through at least Mar 31, 2026. The Board has begun a CEO search. Chairperson Mary Anne Heino will become Executive Chairperson effective Nov 7, 2025 and will act as interim CEO after Markison’s retirement. President Paul Blanchfield is leaving the company; Heino and Markison will assume his responsibilities. Amanda Morgan returns from leave as Chief Commercial Officer reporting to Heino.
The release highlights completed acquisitions (Evergreen Theragnostics, Life Molecular Imaging, Meilleur Technologies) and multiple near-term potential FDA approvals, with management positioning for continued commercial execution.
Lantheus (NASDAQ: LNTH) announced the FDA has set a PDUFA target action date of March 29, 2026 for LNTH-2501 (Gallium-68 edotreotide), a PET diagnostic kit for localization of somatostatin receptor-positive (SSTR+) neuroendocrine tumors in adults and pediatric patients.
The submission was filed under the FDA 505(b)(2) pathway and builds on multiple published studies for Ga-68 edotreotide, positioning LNTH-2501 to expand Lantheus’ oncology diagnostic portfolio and broaden access to SSTR+ NET imaging.
Lantheus (NASDAQ: LNTH) announced the FDA accepted its New Drug Application for MK-6240, an F18-labeled PET imaging agent targeting tau neurofibrillary tangles in patients evaluated for Alzheimer’s disease.
The NDA benefits from prior Fast Track designation and is supported by two pivotal Phase 3 trials that met co-primary endpoints for sensitivity and specificity. The FDA set a PDUFA target action date of August 13, 2026. Company leadership said MK-6240 could complement beta-amyloid PET and blood-based diagnostics if approved.
Lantheus (NASDAQ: LNTH) will host a Third Quarter 2025 earnings conference call and webcast on Thursday, November 6, 2025 at 8:00 a.m. ET to discuss financial results and provide a business update.
Participants should register online at https://investor.lantheus.com/news-events/calendar-of-events and are encouraged to register at least 15 minutes before the start to avoid delays. A replay will be posted about two hours after the webcast and archived on the same page for at least 30 days.